Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.77 |
| ▸ | ESR1 | P03372 | 4/20 | 0.67 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.67 |
| ▸ | HPGD | P15428 | 6/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.61 |
| ▸ | GAA | P10253 | 3/20 | 0.61 |
| ▸ | TP53 | P04637 | 2/20 | 0.61 |
| ▸ | PPARG | P37231 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | PPARD | Q03181 | 1/20 | 0.57 |
| ▸ | PPARA | Q07869 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14185243 | 0.87 | ALDH1A1 (0.75) | ALDH1A1KDM4EESR1ESR2HPGD | |
| SCHEMBL5315268 | 0.87 | ALDH1A1 (0.75) | ALDH1A1KDM4EESR1ESR2HPGD | |
| SCHEMBL5266910 | 0.87 | ALDH1A1 (1.00) | ALDH1A1KDM4EESR1HPGDHSD17B10 | |
| SCHEMBL30991582 | 0.85 | ALDH1A1 (0.71) | ALDH1A1KDM4EESR1HPGDHSD17B10 | |
| SCHEMBL2332295 | 0.85 | ALDH1A1 (0.76) | ALDH1A1KDM4EESR1ESR2HPGD | |
| SCHEMBL2946452 | 0.85 | ALDH1A1 (0.71) | ALDH1A1KDM4EESR1HPGDHSD17B10 | |
| SCHEMBL4941071 | 0.83 | ESR1 (0.64) | ALDH1A1KDM4EESR1ESR2HPGD | |
| SCHEMBL14185242 | 0.82 | PPARG (0.65) | ALDH1A1KDM4EESR1ESR2HPGD | |
| SCHEMBL3957035 | 0.81 | ESR1 (1.00) | ALDH1A1KDM4EESR1ESR2HPGD | |
| SCHEMBL11627119 | 0.81 | MEN1 (0.66) | ALDH1A1KDM4EHPGDHSD17B10GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2247558-B2 | NOVEL IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION | LILLY CO ELI (US) | 2024-07-03 | — | — | EP | disclosed |
| EP-2247558-B1 | NOVEL IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION | LILLY CO ELI (US) | 2022-02-02 | — | — | EP | disclosed |
| EP-2599763-A1 | Novel imaging agents for detecting neurological dysfunction | Siemens Molecular Imaging, Inc. (US) | 2013-06-05 | — | — | EP | disclosed |
| US-8318132-B2 | Imaging agents for detecting neurological dysfunction | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-8318132-B2 | Imaging agents for detecting neurological dysfunction | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-20110091382-A1 | NOVEL IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION | SIEMENS MEDICAL SOLUTION USA, INC. | 2011-04-21 | — | — | US | disclosed |
| US-20110091382-A1 | NOVEL IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION | SIEMENS MEDICAL SOLUTION USA, INC. | 2011-04-21 | — | — | US | disclosed |
| US-20110046378-A1 | Novel Imaging Agents for Detecting Neurological Dysfunction | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-20110046378-A1 | Novel Imaging Agents for Detecting Neurological Dysfunction | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2011-02-24 | — | — | US | disclosed |
| WO-2009102498-A1 | NOVEL IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2009-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110091382-A1 | NOVEL IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION | FABP7, TSPO, SLC18A3 | ALDH1A1 3134/4885KDM4E 4183/4885ESR1 2665/4885 |
| US-20110046378-A1 | Novel Imaging Agents for Detecting Neurological Dysfunction | FABP7, SLC18A3, TSPO | ALDH1A1 3189/4885KDM4E 4258/4885ESR1 2563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.